Medicare prescriptions for Wegovy jumped after approval for heart disease

Дата публикации: 09-07-2026 16:00:01

Medicare prescriptions for Wegovy increased sharply after the program started covering the anti-obesity medication to prevent heart problems, but just a fraction of beneficiaries likely eligible received the treatment, according to new research published in the American Journal of Managed Care by the USC Schaeffer Center for Health Policy & Economics.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Most obesity drugs do not improve quality of life or heart health, analysis indicates	-2	7	08-07-2026
2	GLP-1 use hits record high as Medicare opens access to weight-loss drugs	0	7	09-07-2026
3	7 things to know about Medicare's new GLP-1 coverage	0	7	02-07-2026
4	Wegovy pills 'are just as good as fat jabs when it comes to weight loss - but injections are better for your heart'	0	5	09-07-2026
5	GLP-1 'secret shopper' study finds gaps in online prescribing	0	5	07-07-2026
6	Weight‑loss jabs may create a new kind of yo‑yo dieting	0	7	10-07-2026
7	Thousands with liver disease set to be prescribed weight-loss jab Wegovy, UK drugs watchdog announces	0	7	03-07-2026
8	Statins and blood pressure drugs changing health risks of obesity, study suggests	0	7	01-07-2026
9	Opinion: Who benefits from classifying obesity as a disease?	0	5	09-07-2026
10	Women over 50 lost 35% more weight with this surprising combo	2	7	24-03-2026

Классификация: Экономика. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 7. Источник: medicalxpress.com.